SCOPUS 정보 검색 플랫폼

Volumn 158, Issue 5-6, 2008, Pages 169-173

Early Austrian multicenter experience with palonosetron as antiemetic treatment for patients undergoing highly or moderately emetogenic chemotherapy

(18) Petru, Edgar a Andel, Johannes b Angleitner Boubenizek, Lukas g Steger, Günther b Bernhart, Marianne b Busch, Kerstin f Gehmacher, Otto b Hernler, Tamara d Kastner, Uwe b Lanz Veit, Angelika a Pluschnigg, Ursula b Polachova, Jana a Rohde, Michael e Schiller, Lothar b Schramböck, Rene f Stangl, Wolfgang b Thödtmann, Ralf c Zabernigg, August b

a MEDICAL UNIVERSITY OF GRAZ (Austria)

b MEDICAL UNIVERSITY OF VIENNA (Austria)

c UNIVERSITY OF SALZBURG (Austria)

d Hospital Gaisbühel (Austria)

e Hospital Bregenz (Austria)

f Hietzing Hospital (Austria)

g Krankenhaus der Barmherzigen Schwestern Wien Betriebsgesellschaft (Austria)

Author keywords

5 HT3 receptor antagonists; Antiemetics; Chemotherapy; CINV; Emesis; Nausea; Palonosetron

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; APREPITANT; BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; METOCLOPRAMIDE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PALONOSETRON; PEMETREXED; TREOSULFAN; VINBLASTINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; AGE FACTORS; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; AUSTRIA; BREAST NEOPLASMS; CANCER CARE FACILITIES; FEMALE; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; PRODUCT SURVEILLANCE, POSTMARKETING; QUESTIONNAIRES; QUINUCLIDINES; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN ANTAGONISTS; SEX FACTORS; TIME FACTORS; VOMITING;

EID: 42049114880 PISSN: 00435341 EISSN: None Source Type: Journal
DOI: 10.1007/s10354-008-0515-1 Document Type: Article

Times cited : (6)

References (9)

1
- 0032978412
- Perception of chemotherapy side effects cancer versus noncancer patients
- Lindley C, McCune JS, Thomason TE, Lauder D, Sauls A, Adkins S, Sawyer WT (1999) Perception of chemotherapy side effects cancer versus noncancer patients. Cancer Pract 7: 59-65
- (1999) Cancer Pract , vol.7 , pp. 59-65
- Lindley, C.¹ McCune, J.S.² Thomason, T.E.³ Lauder, D.⁴ Sauls, A.⁵ Adkins, S.⁶ Sawyer, W.T.⁷

2
- 33748749890
- A phase III, double-blind, randomized trial of palonosetron (PAL) compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy
- Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin S, Bertoli L, Yunus F, Morrica B, Lordick F, Macciocchi A (2006) A phase III, double-blind, randomized trial of palonosetron (PAL) compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17: 1441-1449
- (2006) Ann Oncol , vol.17 , pp. 1441-1449
- Aapro, M.S.¹ Grunberg, S.M.² Manikhas, G.M.³ Olivares, G.⁴ Suarez, T.⁵ Tjulandin, S.⁶ Bertoli, L.⁷ Yunus, F.⁸ Morrica, B.⁹ Lordick, F.¹⁰ Macciocchi, A.¹¹

3
- 0344412945
- Improved prevention of moderate CINV with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: Results of a phase III, single-dose trial vs dolasetron
- Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmel A, Macciocchi A, Grunberg S (2003) Improved prevention of moderate CINV with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial vs dolasetron. Cancer 98: 2473-2482
- (2003) Cancer , vol.98 , pp. 2473-2482
- Eisenberg, P.¹ Figueroa-Vadillo, J.² Zamora, R.³ Charu, V.⁴ Hajdenberg, J.⁵ Cartmel, A.⁶ Macciocchi, A.⁷ Grunberg, S.⁸

4
- 10744219621
- Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: Results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron
- Gralla R, Lichinitser M, Van der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14: 1570-1577
- (2003) Ann Oncol , vol.14 , pp. 1570-1577
- Gralla, R.¹ Lichinitser, M.² Van der Vegt, S.³ Sleeboom, H.⁴ Mezger, J.⁵ Peschel, C.⁶ Tonini, G.⁷ Labianca, R.⁸ Macciocchi, A.⁹ Aapro, M.¹⁰

5
- 0031025087
- Proposal for classifying the acute emetogenicity of cancer chemotherapy
- Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, Aapro MS, Gandara D, Lindley CM (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15: 103-109
- (1997) J Clin Oncol , vol.15 , pp. 103-109
- Hesketh, P.J.¹ Kris, M.G.² Grunberg, S.M.³ Beck, T.⁴ Hainsworth, J.D.⁵ Harker, G.⁶ Aapro, M.S.⁷ Gandara, D.⁸ Lindley, C.M.⁹

6
- 29844438029
- MASCC
- MASCC (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the 2004 Perugia international antiemetic consensus conference. Ann Oncol 17: 20-28
- (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: Results of the 2004 Perugia international antiemetic consensus conference. Ann Oncol , vol.17 , pp. 20-28

7
- 33745515076
- American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006
- Kris M, Hesketh P, Somerfield M, Feyer P, Clark-Snow R, Koeller JM, Morrow JR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: Update 2006. J Clin Oncol 24: 2932-2947
- (2006) J Clin Oncol , vol.24 , pp. 2932-2947
- Kris, M.¹ Hesketh, P.² Somerfield, M.³ Feyer, P.⁴ Clark-Snow, R.⁵ Koeller, J.M.⁶ Morrow, J.R.⁷ Chinnery, L.W.⁸ Chesney, M.J.⁹ Gralla, R.J.¹⁰ Grunberg, S.M.¹¹

8
- 0042208365
- Assessment of respondent acceptability of preference measures: Discriminatory power of graphic positioning scale versus traditional scaling measures
- Franic D, Pathak D (2003) Assessment of respondent acceptability of preference measures: discriminatory power of graphic positioning scale versus traditional scaling measures. Value Health 6: 483-493
- (2003) Value Health , vol.6 , pp. 483-493
- Franic, D.¹ Pathak, D.²

9
- 33749640979
- Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: Palonosetron, dexamethasone, and aprepitant; Support
- Grote T, Hajdenberg J, Cartmell A, Ferguson S, Ginkel A, Charu V (2006) Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: Palonosetron, dexamethasone, and aprepitant; Support Oncol 4: 403-408
- (2006) Oncol , vol.4 , pp. 403-408
- Grote, T.¹ Hajdenberg, J.² Cartmell, A.³ Ferguson, S.⁴ Ginkel, A.⁵ Charu, V.⁶

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.